Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 144

1.

Cross-species single-cell analysis of pancreatic ductal adenocarcinoma reveals antigen-presenting cancer-associated fibroblasts.

Elyada E, Bolisetty M, Laise P, Flynn WF, Courtois ET, Burkhart RA, Teinor JA, Belleau P, Biffi G, Lucito MS, Sivajothi S, Armstrong TD, Engle DD, Yu KH, Hao Y, Wolfgang CL, Park Y, Preall J, Jaffee EM, Califano A, Robson P, Tuveson DA.

Cancer Discov. 2019 Jun 13. pii: CD-19-0094. doi: 10.1158/2159-8290.CD-19-0094. [Epub ahead of print]

PMID:
31197017
2.

Oral Mucosal Organoids as a Potential Platform for Personalized Cancer Therapy.

Driehuis E, Kolders S, Spelier S, Lõhmussaar K, Willems SM, Devriese LA, de Bree R, de Ruiter EJ, Korving J, Begthel H, van Es JH, Geurts V, He GW, van Jaarsveld RH, Oka R, Muraro MJ, Vivié J, Zandvliet MMJM, Hendrickx APA, Iakobachvili N, Sridevi P, Kranenburg O, van Boxtel R, Kops GJPL, Tuveson DA, Peters PJ, van Oudenaarden A, Clevers H.

Cancer Discov. 2019 May 3. doi: 10.1158/2159-8290.CD-18-1522. [Epub ahead of print]

PMID:
31053628
3.

A FATal Combination: Fibroblast-Derived Lipids and Cancer-Derived Autotaxin Promote Pancreatic Cancer Growth.

Biffi G, Tuveson DA.

Cancer Discov. 2019 May;9(5):578-580. doi: 10.1158/2159-8290.CD-19-0273.

PMID:
31043410
4.

Organoid models for translational pancreatic cancer research.

Tiriac H, Plenker D, Baker LA, Tuveson DA.

Curr Opin Genet Dev. 2019 Mar 4;54:7-11. doi: 10.1016/j.gde.2019.02.003. [Epub ahead of print] Review.

PMID:
30844513
5.

Deciphering cancer fibroblasts.

Biffi G, Tuveson DA.

J Exp Med. 2018 Dec 3;215(12):2967-2968. doi: 10.1084/jem.20182069. Epub 2018 Nov 23.

6.

TP63-Mediated Enhancer Reprogramming Drives the Squamous Subtype of Pancreatic Ductal Adenocarcinoma.

Somerville TDD, Xu Y, Miyabayashi K, Tiriac H, Cleary CR, Maia-Silva D, Milazzo JP, Tuveson DA, Vakoc CR.

Cell Rep. 2018 Nov 13;25(7):1741-1755.e7. doi: 10.1016/j.celrep.2018.10.051.

7.

Generation and Culture of Tumor and Metastatic Organoids from Murine Models of Pancreatic Ductal Adenocarcinoma.

Baker LA, Tuveson DA.

Methods Mol Biol. 2019;1882:117-133. doi: 10.1007/978-1-4939-8879-2_10.

PMID:
30378048
8.

Generation and Culture of Human Pancreatic Ductal Adenocarcinoma Organoids from Resected Tumor Specimens.

Baker LA, Tiriac H, Tuveson DA.

Methods Mol Biol. 2019;1882:97-115. doi: 10.1007/978-1-4939-8879-2_9.

PMID:
30378047
9.

IL1-Induced JAK/STAT Signaling Is Antagonized by TGFβ to Shape CAF Heterogeneity in Pancreatic Ductal Adenocarcinoma.

Biffi G, Oni TE, Spielman B, Hao Y, Elyada E, Park Y, Preall J, Tuveson DA.

Cancer Discov. 2019 Feb;9(2):282-301. doi: 10.1158/2159-8290.CD-18-0710. Epub 2018 Oct 26.

PMID:
30366930
10.

Stromal biology and therapy in pancreatic cancer: ready for clinical translation?

Neesse A, Bauer CA, Öhlund D, Lauth M, Buchholz M, Michl P, Tuveson DA, Gress TM.

Gut. 2019 Jan;68(1):159-171. doi: 10.1136/gutjnl-2018-316451. Epub 2018 Sep 3. Review.

PMID:
30177543
11.

Real-time Genomic Characterization of Advanced Pancreatic Cancer to Enable Precision Medicine.

Aguirre AJ, Nowak JA, Camarda ND, Moffitt RA, Ghazani AA, Hazar-Rethinam M, Raghavan S, Kim J, Brais LK, Ragon D, Welch MW, Reilly E, McCabe D, Marini L, Anderka K, Helvie K, Oliver N, Babic A, Da Silva A, Nadres B, Van Seventer EE, Shahzade HA, St Pierre JP, Burke KP, Clancy T, Cleary JM, Doyle LA, Jajoo K, McCleary NJ, Meyerhardt JA, Murphy JE, Ng K, Patel AK, Perez K, Rosenthal MH, Rubinson DA, Ryou M, Shapiro GI, Sicinska E, Silverman SG, Nagy RJ, Lanman RB, Knoerzer D, Welsch DJ, Yurgelun MB, Fuchs CS, Garraway LA, Getz G, Hornick JL, Johnson BE, Kulke MH, Mayer RJ, Miller JW, Shyn PB, Tuveson DA, Wagle N, Yeh JJ, Hahn WC, Corcoran RB, Carter SL, Wolpin BM.

Cancer Discov. 2018 Sep;8(9):1096-1111. doi: 10.1158/2159-8290.CD-18-0275. Epub 2018 Jun 14.

PMID:
29903880
12.

Organoid Profiling Identifies Common Responders to Chemotherapy in Pancreatic Cancer.

Tiriac H, Belleau P, Engle DD, Plenker D, Deschênes A, Somerville TDD, Froeling FEM, Burkhart RA, Denroche RE, Jang GH, Miyabayashi K, Young CM, Patel H, Ma M, LaComb JF, Palmaira RLD, Javed AA, Huynh JC, Johnson M, Arora K, Robine N, Shah M, Sanghvi R, Goetz AB, Lowder CY, Martello L, Driehuis E, LeComte N, Askan G, Iacobuzio-Donahue CA, Clevers H, Wood LD, Hruban RH, Thompson E, Aguirre AJ, Wolpin BM, Sasson A, Kim J, Wu M, Bucobo JC, Allen P, Sejpal DV, Nealon W, Sullivan JD, Winter JM, Gimotty PA, Grem JL, DiMaio DJ, Buscaglia JM, Grandgenett PM, Brody JR, Hollingsworth MA, O'Kane GM, Notta F, Kim E, Crawford JM, Devoe C, Ocean A, Wolfgang CL, Yu KH, Li E, Vakoc CR, Hubert B, Fischer SE, Wilson JM, Moffitt R, Knox J, Krasnitz A, Gallinger S, Tuveson DA.

Cancer Discov. 2018 Sep;8(9):1112-1129. doi: 10.1158/2159-8290.CD-18-0349. Epub 2018 May 31.

PMID:
29853643
13.

Macrophage-Derived Granulin Drives Resistance to Immune Checkpoint Inhibition in Metastatic Pancreatic Cancer.

Quaranta V, Rainer C, Nielsen SR, Raymant ML, Ahmed MS, Engle DD, Taylor A, Murray T, Campbell F, Palmer DH, Tuveson DA, Mielgo A, Schmid MC.

Cancer Res. 2018 Aug 1;78(15):4253-4269. doi: 10.1158/0008-5472.CAN-17-3876. Epub 2018 May 22.

14.

Patient-derived organoid models help define personalized management of gastrointestinal cancer.

Aberle MR, Burkhart RA, Tiriac H, Olde Damink SWM, Dejong CHC, Tuveson DA, van Dam RM.

Br J Surg. 2018 Jan;105(2):e48-e60. doi: 10.1002/bjs.10726. Review.

15.

Successful creation of pancreatic cancer organoids by means of EUS-guided fine-needle biopsy sampling for personalized cancer treatment.

Tiriac H, Bucobo JC, Tzimas D, Grewel S, Lacomb JF, Rowehl LM, Nagula S, Wu M, Kim J, Sasson A, Vignesh S, Martello L, Munoz-Sagastibelza M, Somma J, Tuveson DA, Li E, Buscaglia JM.

Gastrointest Endosc. 2018 Jun;87(6):1474-1480. doi: 10.1016/j.gie.2017.12.032. Epub 2018 Jan 9.

16.

Soils and Seeds That Initiate Pancreatic Cancer Metastasis.

Vakoc CR, Tuveson DA.

Cancer Discov. 2017 Oct;7(10):1067-1068. doi: 10.1158/2159-8290.CD-17-0887.

17.

Transcriptional Regulation by Nrf2.

Tonelli C, Chio IIC, Tuveson DA.

Antioxid Redox Signal. 2018 Dec 10;29(17):1727-1745. doi: 10.1089/ars.2017.7342. Epub 2017 Oct 20.

18.

Enhancer Reprogramming Promotes Pancreatic Cancer Metastasis.

Roe JS, Hwang CI, Somerville TDD, Milazzo JP, Lee EJ, Da Silva B, Maiorino L, Tiriac H, Young CM, Miyabayashi K, Filippini D, Creighton B, Burkhart RA, Buscaglia JM, Kim EJ, Grem JL, Lazenby AJ, Grunkemeyer JA, Hollingsworth MA, Grandgenett PM, Egeblad M, Park Y, Tuveson DA, Vakoc CR.

Cell. 2017 Aug 24;170(5):875-888.e20. doi: 10.1016/j.cell.2017.07.007. Epub 2017 Jul 27.

19.

Recurrent noncoding regulatory mutations in pancreatic ductal adenocarcinoma.

Feigin ME, Garvin T, Bailey P, Waddell N, Chang DK, Kelley DR, Shuai S, Gallinger S, McPherson JD, Grimmond SM, Khurana E, Stein LD, Biankin AV, Schatz MC, Tuveson DA.

Nat Genet. 2017 Jun;49(6):825-833. doi: 10.1038/ng.3861. Epub 2017 May 8.

20.

ROS in Cancer: The Burning Question.

Chio IIC, Tuveson DA.

Trends Mol Med. 2017 May;23(5):411-429. doi: 10.1016/j.molmed.2017.03.004. Epub 2017 Apr 17. Review.

21.

Quid pro Quo: A Tumor is Not Alone.

Sacristán C, Tuveson DA.

Trends Mol Med. 2017 May;23(5):375-376. doi: 10.1016/j.molmed.2017.03.007. Epub 2017 Apr 10. No abstract available.

PMID:
28408271
22.

Challenges and Opportunities in Modeling Pancreatic Cancer.

Feigin ME, Tuveson DA.

Cold Spring Harb Symp Quant Biol. 2016;81:231-235. doi: 10.1101/sqb.2016.81.031104. Epub 2017 Mar 13. Review.

PMID:
28289164
23.

Untangling the genetics from the epigenetics in pancreatic cancer metastasis.

Vakoc CR, Tuveson DA.

Nat Genet. 2017 Feb 24;49(3):323-324. doi: 10.1038/ng.3798.

PMID:
28232730
24.

Distinct populations of inflammatory fibroblasts and myofibroblasts in pancreatic cancer.

Öhlund D, Handly-Santana A, Biffi G, Elyada E, Almeida AS, Ponz-Sarvise M, Corbo V, Oni TE, Hearn SA, Lee EJ, Chio II, Hwang CI, Tiriac H, Baker LA, Engle DD, Feig C, Kultti A, Egeblad M, Fearon DT, Crawford JM, Clevers H, Park Y, Tuveson DA.

J Exp Med. 2017 Mar 6;214(3):579-596. doi: 10.1084/jem.20162024. Epub 2017 Feb 23.

25.

Rapid and tunable method to temporally control gene editing based on conditional Cas9 stabilization.

Senturk S, Shirole NH, Nowak DG, Corbo V, Pal D, Vaughan A, Tuveson DA, Trotman LC, Kinney JB, Sordella R.

Nat Commun. 2017 Feb 22;8:14370. doi: 10.1038/ncomms14370.

26.

Cancer: Double trouble for tumours.

Biffi G, Tuveson DA.

Nature. 2017 Feb 2;542(7639):34-35. doi: 10.1038/nature21117. Epub 2017 Jan 18. No abstract available.

PMID:
28099410
27.

Chemoresistance in Pancreatic Cancer Is Driven by Stroma-Derived Insulin-Like Growth Factors.

Ireland L, Santos A, Ahmed MS, Rainer C, Nielsen SR, Quaranta V, Weyer-Czernilofsky U, Engle DD, Perez-Mancera PA, Coupland SE, Taktak A, Bogenrieder T, Tuveson DA, Campbell F, Schmid MC, Mielgo A.

Cancer Res. 2016 Dec 1;76(23):6851-6863. doi: 10.1158/0008-5472.CAN-16-1201. Epub 2016 Oct 14.

28.

ROS in translation: Chink in the armor.

Chio II, Tuveson DA.

Cell Cycle. 2017 Feb 16;16(4):297-298. doi: 10.1080/15384101.2016.1232087. Epub 2016 Sep 16. No abstract available.

29.

NRF2 Promotes Tumor Maintenance by Modulating mRNA Translation in Pancreatic Cancer.

Chio IIC, Jafarnejad SM, Ponz-Sarvise M, Park Y, Rivera K, Palm W, Wilson J, Sangar V, Hao Y, Öhlund D, Wright K, Filippini D, Lee EJ, Da Silva B, Schoepfer C, Wilkinson JE, Buscaglia JM, DeNicola GM, Tiriac H, Hammell M, Crawford HC, Schmidt EE, Thompson CB, Pappin DJ, Sonenberg N, Tuveson DA.

Cell. 2016 Aug 11;166(4):963-976. doi: 10.1016/j.cell.2016.06.056. Epub 2016 Jul 28.

30.

Corrigendum: Macrophage-secreted granulin supports pancreatic cancer metastasis by inducing liver fibrosis.

Nielsen SR, Quaranta V, Linford A, Emeagi P, Rainer C, Santos A, Ireland L, Sakai T, Sakai K, Kim YS, Engle D, Campbell F, Palmer D, Ko JH, Tuveson DA, Hirsch E, Mielgo A, Schmid MC.

Nat Cell Biol. 2016 Jun 28;18(7):822. doi: 10.1038/ncb3377. No abstract available.

PMID:
27350447
31.

Model organoids provide new research opportunities for ductal pancreatic cancer.

Boj SF, Hwang CI, Baker LA, Engle DD, Tuveson DA, Clevers H.

Mol Cell Oncol. 2015 Feb 23;3(1):e1014757. doi: 10.1080/23723556.2015.1014757. eCollection 2016 Jan.

32.

Conjugation to the sigma-2 ligand SV119 overcomes uptake blockade and converts dm-Erastin into a potent pancreatic cancer therapeutic.

Ohman KA, Hashim YM, Vangveravong S, Nywening TM, Cullinan DR, Goedegebuure SP, Liu J, Van Tine BA, Tiriac H, Tuveson DA, DeNardo DG, Spitzer D, Mach RH, Hawkins WG.

Oncotarget. 2016 Jun 7;7(23):33529-41. doi: 10.18632/oncotarget.9551.

33.

Pancreatic cancer.

Kleeff J, Korc M, Apte M, La Vecchia C, Johnson CD, Biankin AV, Neale RE, Tempero M, Tuveson DA, Hruban RH, Neoptolemos JP.

Nat Rev Dis Primers. 2016 Apr 21;2:16022. doi: 10.1038/nrdp.2016.22. Review.

PMID:
27158978
34.

Modeling pancreatic cancer with organoids.

Baker LA, Tiriac H, Clevers H, Tuveson DA.

Trends Cancer. 2016 Apr;2(4):176-190.

35.

Macrophage-secreted granulin supports pancreatic cancer metastasis by inducing liver fibrosis.

Nielsen SR, Quaranta V, Linford A, Emeagi P, Rainer C, Santos A, Ireland L, Sakai T, Sakai K, Kim YS, Engle D, Campbell F, Palmer D, Ko JH, Tuveson DA, Hirsch E, Mielgo A, Schmid MC.

Nat Cell Biol. 2016 May;18(5):549-60. doi: 10.1038/ncb3340. Epub 2016 Apr 18. Erratum in: Nat Cell Biol. 2016 Jun 28;18(7):822.

36.

Generation and Characterisation of a Pax8-CreERT2 Transgenic Line and a Slc22a6-CreERT2 Knock-In Line for Inducible and Specific Genetic Manipulation of Renal Tubular Epithelial Cells.

Espana-Agusti J, Zou X, Wong K, Fu B, Yang F, Tuveson DA, Adams DJ, Matakidou A.

PLoS One. 2016 Feb 11;11(2):e0148055. doi: 10.1371/journal.pone.0148055. eCollection 2016.

37.

Decreased Serum Thrombospondin-1 Levels in Pancreatic Cancer Patients Up to 24 Months Prior to Clinical Diagnosis: Association with Diabetes Mellitus.

Jenkinson C, Elliott VL, Evans A, Oldfield L, Jenkins RE, O'Brien DP, Apostolidou S, Gentry-Maharaj A, Fourkala EO, Jacobs IJ, Menon U, Cox T, Campbell F, Pereira SP, Tuveson DA, Park BK, Greenhalf W, Sutton R, Timms JF, Neoptolemos JP, Costello E.

Clin Cancer Res. 2016 Apr 1;22(7):1734-1743. doi: 10.1158/1078-0432.CCR-15-0879. Epub 2015 Nov 16.

38.

BAG3 promotes pancreatic ductal adenocarcinoma growth by activating stromal macrophages.

Rosati A, Basile A, D'Auria R, d'Avenia M, De Marco M, Falco A, Festa M, Guerriero L, Iorio V, Parente R, Pascale M, Marzullo L, Franco R, Arra C, Barbieri A, Rea D, Menichini G, Hahne M, Bijlsma M, Barcaroli D, Sala G, di Mola FF, di Sebastiano P, Todoric J, Antonucci L, Corvest V, Jawhari A, Firpo MA, Tuveson DA, Capunzo M, Karin M, De Laurenzi V, Turco MC.

Nat Commun. 2015 Nov 2;6:8695. doi: 10.1038/ncomms9695.

39.

Preclinical models of pancreatic ductal adenocarcinoma.

Hwang CI, Boj SF, Clevers H, Tuveson DA.

J Pathol. 2016 Jan;238(2):197-204. doi: 10.1002/path.4651. Epub 2015 Nov 14. Review.

40.

MRI with hyperpolarised [1-13C]pyruvate detects advanced pancreatic preneoplasia prior to invasive disease in a mouse model.

Serrao EM, Kettunen MI, Rodrigues TB, Dzien P, Wright AJ, Gopinathan A, Gallagher FA, Lewis DY, Frese KK, Almeida J, Howat WJ, Tuveson DA, Brindle KM.

Gut. 2016 Mar;65(3):465-75. doi: 10.1136/gutjnl-2015-310114. Epub 2015 Sep 7.

41.

Mouse Models of Pancreatic Ductal Adenocarcinoma.

Ponz-Sarvise M, Tuveson DA, Yu KH.

Hematol Oncol Clin North Am. 2015 Aug;29(4):609-17. doi: 10.1016/j.hoc.2015.04.010. Epub 2015 Jun 11. Review.

PMID:
26226900
42.

The Utilization of Extracellular Proteins as Nutrients Is Suppressed by mTORC1.

Palm W, Park Y, Wright K, Pavlova NN, Tuveson DA, Thompson CB.

Cell. 2015 Jul 16;162(2):259-270. doi: 10.1016/j.cell.2015.06.017. Epub 2015 Jul 2.

43.

A minimally invasive, lentiviral based method for the rapid and sustained genetic manipulation of renal tubules.

Espana-Agusti J, Tuveson DA, Adams DJ, Matakidou A.

Sci Rep. 2015 Jun 5;5:11061. doi: 10.1038/srep11061.

44.

Stromal biology and therapy in pancreatic cancer: a changing paradigm.

Neesse A, Algül H, Tuveson DA, Gress TM.

Gut. 2015 Sep;64(9):1476-84. doi: 10.1136/gutjnl-2015-309304. Epub 2015 May 20. Review.

PMID:
25994217
45.

ADAM8 as a drug target in pancreatic cancer.

Schlomann U, Koller G, Conrad C, Ferdous T, Golfi P, Garcia AM, Höfling S, Parsons M, Costa P, Soper R, Bossard M, Hagemann T, Roshani R, Sewald N, Ketchem RR, Moss ML, Rasmussen FH, Miller MA, Lauffenburger DA, Tuveson DA, Nimsky C, Bartsch JW.

Nat Commun. 2015 Jan 28;6:6175. doi: 10.1038/ncomms7175.

46.

BRAF inhibitor resistance mediated by the AKT pathway in an oncogenic BRAF mouse melanoma model.

Perna D, Karreth FA, Rust AG, Perez-Mancera PA, Rashid M, Iorio F, Alifrangis C, Arends MJ, Bosenberg MW, Bollag G, Tuveson DA, Adams DJ.

Proc Natl Acad Sci U S A. 2015 Feb 10;112(6):E536-45. doi: 10.1073/pnas.1418163112. Epub 2015 Jan 26.

47.

Identification of novel vascular projections with cellular trafficking abilities on the microvasculature of pancreatic ductal adenocarcinoma.

Hexige S, Ardito-Abraham CM, Wu Y, Wei Y, Fang Y, Han X, Li J, Zhou P, Yi Q, Maitra A, Liu JO, Tuveson DA, Lou W, Yu L.

J Pathol. 2015 Jun;236(2):142-154. doi: 10.1002/path.4506. Epub 2015 Feb 17.

48.

Organoid models of human and mouse ductal pancreatic cancer.

Boj SF, Hwang CI, Baker LA, Chio II, Engle DD, Corbo V, Jager M, Ponz-Sarvise M, Tiriac H, Spector MS, Gracanin A, Oni T, Yu KH, van Boxtel R, Huch M, Rivera KD, Wilson JP, Feigin ME, Öhlund D, Handly-Santana A, Ardito-Abraham CM, Ludwig M, Elyada E, Alagesan B, Biffi G, Yordanov GN, Delcuze B, Creighton B, Wright K, Park Y, Morsink FH, Molenaar IQ, Borel Rinkes IH, Cuppen E, Hao Y, Jin Y, Nijman IJ, Iacobuzio-Donahue C, Leach SD, Pappin DJ, Hammell M, Klimstra DS, Basturk O, Hruban RH, Offerhaus GJ, Vries RG, Clevers H, Tuveson DA.

Cell. 2015 Jan 15;160(1-2):324-38. doi: 10.1016/j.cell.2014.12.021. Epub 2014 Dec 31.

49.

p53 mutations change phosphatidylinositol acyl chain composition.

Naguib A, Bencze G, Engle DD, Chio II, Herzka T, Watrud K, Bencze S, Tuveson DA, Pappin DJ, Trotman LC.

Cell Rep. 2015 Jan 6;10(1):8-19. doi: 10.1016/j.celrep.2014.12.010. Epub 2014 Dec 24.

50.

Vitamin D receptor-mediated stromal reprogramming suppresses pancreatitis and enhances pancreatic cancer therapy.

Sherman MH, Yu RT, Engle DD, Ding N, Atkins AR, Tiriac H, Collisson EA, Connor F, Van Dyke T, Kozlov S, Martin P, Tseng TW, Dawson DW, Donahue TR, Masamune A, Shimosegawa T, Apte MV, Wilson JS, Ng B, Lau SL, Gunton JE, Wahl GM, Hunter T, Drebin JA, O'Dwyer PJ, Liddle C, Tuveson DA, Downes M, Evans RM.

Cell. 2014 Sep 25;159(1):80-93. doi: 10.1016/j.cell.2014.08.007.

Supplemental Content

Loading ...
Support Center